Candidate Compounds Covid19

(Unterschied zwischen Versionen)
Wechseln zu: Navigation, Suche
K
(42 dazwischenliegende Versionen von einem Benutzer werden nicht angezeigt)
Zeile 1: Zeile 1:
 
{{pnc}}
 
{{pnc}}
 +
{{ft|P}}
 +
...so calm down and enjoy the progress of immediate translational medicine:
 +
A concept of curative retargeting has been found by cellular lockdown with kinase inhibitors from the oncologic pharmacopoiea.
 +
This means, virus replication can be stalled to zero w/o need of develpoment of new substances. There is no need for world
 +
vaccination anymore. The virus needs permissible cells, and most perimissible is phosphotyrosine on its own compnents.
 +
Paper is (not yet in PubMed) :
  
current items will be put into the subsections.
+
*'''[https://www.sciencedirect.com/science/article/pii/S1097276520305499?via%3Dihub Growth factor receptor signaling inhibition prevents SARS-CoV-2 replication at Mol Cell 2020/08/11]'''
subsections with contents are marked ''with content''.
+
credentials to [https://web.de/magazine/news/coronavirus/coronavirus-blockade-zellulaerer-kommunikation-forscher-stoppen-vermehrung-sars-cov-2-35045170 Marinus Brandl] who told us about it today.
the others are pending data.
+
based on e.g.
  
*[[reviews on covid drug development]] ''with content''
+
{{ttp|p=32408336|t=2020. Proteomics of SARS-CoV-2-infected host cells reveals therapy targets |pdf=|usr=}}
 +
 
 +
=======================================================================================
 +
 
 +
COVID19 is now a CURABLE disease !!!
 +
 
 +
=======================================================================================
 +
 
 +
*[[reviews on covid drug development]]  
 
*[[scouting ideas]]
 
*[[scouting ideas]]
  
 
*[[Patients on biologicals]]
 
*[[Patients on biologicals]]
 
*[[HMGB1, RAGE]]
 
*[[HMGB1, RAGE]]
*[[pre-Interleukin 6]] ''with content''
+
*[[pre-Interleukin 6]]  
 
*[[post-Interleukin 6]]
 
*[[post-Interleukin 6]]
 
*[[pre-TNFalpha]]
 
*[[pre-TNFalpha]]
Zeile 18: Zeile 32:
 
*[[pre-Interleukin 1]]
 
*[[pre-Interleukin 1]]
 
*[[post-Interleukin 1]]
 
*[[post-Interleukin 1]]
*[[Inflammasome]]
+
*[[Inflammasome]] ''colchicine''
 +
*[[Methotrexate]]
 
*[[other anti-inflammatory]]
 
*[[other anti-inflammatory]]
 
*[[NK-kappaB]]
 
*[[NK-kappaB]]
Zeile 27: Zeile 42:
 
*[[Target Complement system]]
 
*[[Target Complement system]]
 
*[[Target Extracellular traps]]
 
*[[Target Extracellular traps]]
 +
*[[Caplacizumab]] vWF(TTP)
 +
*[[Target Neurophils]]
 +
*[[Target Mast cells]] and kinins
 +
*[[TGF beta]]
 +
*[[Immunosuppressants]]
 
*[[Anticoagulant in covid19]]
 
*[[Anticoagulant in covid19]]
 
*[[Antioxidants]]
 
*[[Antioxidants]]
 +
*[[HIF-EPO-Iron]]
 
*[[Stem cells]]
 
*[[Stem cells]]
 
*[[MDSC cells]]
 
*[[MDSC cells]]
 
+
*[[Interferons]]
 +
*[[cAMP cGMP PDE NO]]
 +
*[[TRPV* channels]]
 +
*[[Retinoids]]
 +
*[[Protease inhibitors]]
 +
*[[Tyrosine kinase inhibitors]]
 +
*[[Antineoplastic agents, traditional]]
 +
*[[Mouthrinses]]
 +
*[[Adenosinergic signaling]]
 +
*[[Purinergic signaling]]
 +
*[[Nicotinergic signaling]]
  
  
 
*[[other single compounds]]
 
*[[other single compounds]]
*[[Retargeted single compounds]]
+
*[[Retargeted Psychopharm]]
*[[Hydroxychloroquine]] ''with content''
+
*[[Hydroxychloroquine]]  
 
*
 
*
 
+
*[[Target ACE2, Spike protein]]
 +
*[[Target TMPRSS2, Spike protein]] ''any other covid targed herein''
 +
*[[Aprotinin]] protease inh bradykinin synth. inh.
 
*[[other antiviral compounds]]
 
*[[other antiviral compounds]]
 
*[[AV Remdesivir]]
 
*[[AV Remdesivir]]
 
*[[AV Lopinavir]]
 
*[[AV Lopinavir]]
 
*[[AV Ivermectin]]
 
*[[AV Ivermectin]]
 +
*[[AV Arabidol]]
 +
*[[AV Favipiravir]]
  
*[[Target ACE2, Spike protein]]
+
*[[Antibiotics]]
*[[Target TMPRSS2, Spike protein]]
+
 
+
 
+
 
+
*[[Interferons]]
+
 
+
  
  
 
*[[Vitamin D]]
 
*[[Vitamin D]]
 
*[[Statins]]
 
 
*[[Anorganic nutrients Magnesium]]
 
*[[Anorganic nutrients Magnesium]]
 
*[[Anorganic nutrients Selenium]]
 
*[[Anorganic nutrients Selenium]]
 
*[[Anorganic nutrients Zinc]]
 
*[[Anorganic nutrients Zinc]]
 
+
*[[Anorganic nutrients Lithium]]
 +
*[[Anorganic nutrients Copper]]
 +
*[[Anorganic nutrients Bismuth]]
 +
*[[Nutrition, general]]
 +
*[[Exercise, Vibration]]
  
  
Zeile 65: Zeile 96:
 
*[[Natural compounds]]
 
*[[Natural compounds]]
  
 +
*[[Statins]]
 
*[[Antidiabetic compounds, any]]
 
*[[Antidiabetic compounds, any]]
 
*[[RSP - On RAS drugs]]
 
*[[RSP - On RAS drugs]]
 +
*[[RSP - On NSAIDs]]
  
*[[Reconvalescent blood products, Passive vaccine]] ''with content''
+
*[[Reconvalescent blood products, Passive vaccine]]  
 
*[[Plasmapheresis]]
 
*[[Plasmapheresis]]
  
 
*[[Immunodeviation]] e.g. by adjuvants or other vaccinations
 
*[[Immunodeviation]] e.g. by adjuvants or other vaccinations
 
*[[Radiation therapy]]
 
*[[Radiation therapy]]
*[[Active vaccine]] ''with content''
+
*[[Phototherapy]]
 
+
*[[Active vaccine]]  
 
+
 
+
 
+
 
+
 
+
 
+
 
+
 
+
 
+
 
+
 
+
 
+
 
+
 
+
 
+
 
+
 
+
 
+
 
+
 
+
 
+
 
+
 
+
 
+
 
+
 
+
 
+
 
+
 
+
 
+
 
+
 
+
 
+
 
+
 
+
 
+
 
+
 
+
 
+
 
+
 
+
 
+
 
+
 
+
'''resilience enhancement'''
+
{{tp|p=32229705|t=2020. Geroprotective and senoremediative strategies to reduce the comorbidity, infection rates, severity, and lethality in gerophilic and gerolavic infections |pdf=|usr=}}
+
{{tp|p=32311498|t=ä. The impact of nutrition on COVID-19 susceptibility and long-term consequences |pdf=|usr=}}
+
{{tp|p=32276453|t=2020. Exploring the Relevance of Senotherapeutics for the Current SARS-CoV-2 Emergency  and Similar Future Global Health Threats |pdf=|usr=}}
+
 
+
'''psychoneuroimmunology'''
+
{{tp|p=32234338|t=ä. Using psychoneuroimmunity against COVID-19 |pdf=|usr=}}
+
 
+
 
+
 
+
 
+
'''Exercise'''
+
{{tp|p=32311497|t=ä. The immunological case for staying active during the COVID-19 pandemic |pdf=|usr=}}
+
 
+
'''Topical agents''' opening up the world of nano...
+
*[https://www.dailymail.co.uk/sciencetech/article-8315269/Commercial-mouthwash-prevent-COVID-19-transmission-scientists-say.html on mouth rinses]
+
 
+
 
+
 
+
 
+
 
+
  
 +
*[[Treatment other concepts]]
 
----
 
----
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
{{tp|p=32305181|t=ä. ESPEN expert statements and practical guidance for nutritional management of individuals with SARS-CoV-2 infection |pdf=|usr=}}
 
{{tp|p=32360083|t=ä. Modulation of Hb-O2 affinity to improve hypoxemia in COVID-19 patients |pdf=|usr=}}
 
 
{{tp|p=32277367|t=ä. Rheumatologists? perspective on coronavirus disease 19 (COVID-19) and potential therapeutic targets |pdf=|usr=}}
 
{{tp|p=32373721|t=2020. Low dose lung radiotherapy for COVID-19 pneumonia  The rationale for a cost-effective anti-inflammatory treatment |pdf=|usr=}}
 
 
 
 
 
 
 
 
 
{{tp|p=32318324|t=ä. Depriving Iron Supply to the Virus Represents a Promising Adjuvant Therapeutic Against Viral Survival |pdf=|usr=}}
 
 
 
{{tp|p=32360420|t=ä. Cytokine storm intervention in the early stages of COVID-19 pneumonia |pdf=|usr=}}
 
 
 
 
{{tp|p=32335366|t=2020. Can dapagliflozin have a protective effect against COVID-19 infection? A hypothesis |pdf=|usr=}}
 
{{tp|p=32333972|t=ä. Letter to the Editor in response to the article ?COVID-19 and diabetes: Can DPP4  inhibition play a role?? |pdf=|usr=}}
 
{{tp|p=32333966|t=2020. COVID-19 and diabetes: Is this association driven by the DPP4 receptor? Potential clinical and therapeutic implications |pdf=|usr=}}
 
{{tp|p=32333969|t=ä. Response to COVID -19 and Diabetes: Can DPP4 Inhibition Play a Role? ? GLP-1 Might Play One Too |pdf=|usr=}}
 
{{tp|p=32283128|t=ä. Should anti-diabetic medications be reconsidered amid COVID-19 pandemic?|pdf=|usr=}} ''on ace2 via adam17, nfkb via dpp4''
 
 
 
 
 
 
 
 
 
{{tp|p=32325124|t=ä. Vaporization, bioactive formulations and a marine natural product: different perspectives on antivirals |pdf=|usr=}}
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
{{tp|p=32271462|t=2020. Inositol and pulmonary function  Could myo-inositol treatment downregulate inflammation and cytokine release syndrome in SARS-CoV-2?|pdf=|usr=}}
 
 
 
 
 
 
 
 
 
{{tp|p=32312129|t=2020. The role of additive manufacturing and antimicrobial polymers in the COVID-19 pandemic |pdf=|usr=}}
 
{{tp|p=32117569|t=2020. Therapeutic strategies in an outbreak scenario to treat the novel coronavirus originating in Wuhan, China |pdf=|usr=}}
 
 
 
 
 
 
 
 
 
{{tp|p=32247692|t=ä. Faecal-oral transmission of SARS-COV-2: practical implications |pdf=|usr=}}
 
{{tp|p=32367287|t=ä. New evidence of SARS-CoV-2 transmission through the ocular surface |pdf=|usr=}}
 
 
 
{{tp|p=32251365|t=ä. Considering mutational meltdown as a potential SARS-CoV-2 treatment strategy |pdf=|usr=}}
 
 
 
 
 
 
 
 
{{tp|p=32366728|t=2020. Medical Education During the COVID-19 Pandemic: A Single Institution Experience |pdf=|usr=}}
 
{{tp|p=32366726|t=2020. Management of Asthma in Children during COVID-19 Pandemic |pdf=|usr=}}
 
{{tp|p=32366725|t=2020. COVID -19 Pandemic: The Challenges for Pediatric Oncology |pdf=|usr=}}
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
{{tp|p=32283177|t=ä. Coronavirus (COVID-19), First Indication of Efficacy of Gene-Eden-VIR/Novirin in  SARS-CoV-2 Infections |pdf=|usr=}}
 
 
 
 
 
{{tp|p=32226290|t=2020. Targeting the Endocytic Pathway and Autophagy Process as a Novel Therapeutic Strategy in COVID-19 |pdf=|usr=}}
 
 
 
 
 
 
 
 
{{tp|p=32305009|t=ä. Investigating hypothiocyanite against SARS-CoV-2 |pdf=|usr=}}
 
 
 
{{tp|p=32354030|t=2020. Functional Role of Dietary Intervention to Improve the Outcome of COVID-19: A Hypothesis of Work |pdf=|usr=}}
 
 
 
 
 
 
 
 
 
 
 
 
 
 
{{tp|p=32336674|t=ä. COVID-19 Emergency Responders in FDA?s Center for Drug Evaluation and Research |pdf=|usr=}}
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
{{tp|p=32326426|t=2020. COVID-19: A Recommendation to Examine the Effect of Mouthrinses with beta-Cyclodextrin Combined with Citrox in Preventing Infection and Progression |pdf=|usr=}}
 
 
 
 
 
 
 
 
 
 
 
{{tp|p=32373322|t=ä. Fighting COVID-19 with water |pdf=|usr=}}''dehydration of mucous glycans''
 
 
 
 
 
 
 
 
 
 
 
 
 
{{tp|p=32356251|t=ä. Medical Toxicology and COVID-19: Our Role in a Pandemic |pdf=|usr=}}
 
 
 
 
 
 
 
 
 
 
 
 
 
{{tp|p=32324533|t=2020. Prevention and therapy of COVID-19 via exogenous estrogen treatment for both male and female patients |pdf=|usr=}}
 
 
{{tp|p=32291198|t=2020. Impact of Nutrition and Diet on COVID-19 Infection and Implications for Kidney Health and Kidney Disease Management |pdf=|usr=}}
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
{{tp|p=32339473|t=ä. Probiotics and COVID-19: one size does not fit all |pdf=|usr=}}
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*''riociguat?''
 
 
 
 
 
 
 
 
 
 
 
{{tp|p=32344313|t=ä. Can pioglitazone be potentially useful therapeutically in treating patients with  covid-19?|pdf=|usr=}}
 
{{tp|p=32344312|t=2020. Potential effect of natural and anabolizan steroids in elderly patient with COVID-19 |pdf=|usr=}}
 
{{tp|p=32344310|t=2020. Respiratory conditions in coronavirus disease 2019 (COVID-19): Important considerations regarding novel treatment strategies to reduce mortality |pdf=|usr=}}
 
 
 
 
{{tp|p=32335456|t=2020. The old but new: Can unfractioned heparin and low molecular weight heparins inhibit proteolytic activation and cellular internalization of SARS-CoV2 by inhibition of host cell proteases?|pdf=|usr=}}
 
 
 
{{tp|p=32353355|t=ä. Testosterone, a key hormone in the context of COVID-19 pandemic |pdf=|usr=}}
 
 
 
{{tp|p=32255312|t=2020. A possible probiotic (S  salivarius K12) approach to improve oral and lung microbiotas and raise defenses against SARS-CoV-2 |pdf=|usr=}}
 
{{tp|p=32365556|t=2020. Pharmacological (or Synthetic) and Nutritional Agonists of PPAR-gamma as Candidates for Cytokine Storm Modulation in COVID-19 Disease |pdf=|usr=}}
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
{{tp|p=32340216|t=2020. Optimal Nutritional Status for a Well-Functioning Immune System Is an Important Factor to Protect against Viral Infections |pdf=|usr=}}
 
 
{{tp|p=32342019|t=ä. Exercise against SARS-CoV-2 (COVID-19): Does workout intensity matter? (A mini review of some indirect evidence related to obesity) |pdf=|usr=}}
 
 
 
 
 
{{tp|p=32307559|t=ä. Management for patients with pediatric surgical disease during the COVID-19 epidemic |pdf=|usr=}}
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
{{tp|p=32342871|t=ä. Is low dose radiation therapy a potential treatment for COVID-19 pneumonia?|pdf=|usr=}}
 
{{tp|p=32342874|t=ä. Low dose radiation therapy for COVID-19 pneumonia: a double-edged sword |pdf=|usr=}}
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
{{tp|p=32297156|t=ä. Computational Identification of Small Interfering RNA Targets in SARS-CoV-2 |pdf=|usr=}}
 
 
 
 
 
 
 
 
 
 
 
 
{{tp|p=32191676|t=2020. Natural small molecules as inhibitors of coronavirus lipid-dependent attachment to host cells: a possible strategy for reducing SARS-COV-2 infectivity?|pdf=|usr=}}
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
{{tp|p=32229155|t=2020. Can Bioactive Lipids Inactivate Coronavirus (COVID-19)?|pdf=|usr=}}
 
 
{{tp|p=32282033|t=2020. Initiating adjunct low-dose hydroxyurea therapy for stroke prevention in children with SCA during the COVID-19 pandemic |pdf=|usr=}}
 
{{tp|p=32362106|t=2020. Management of conjunctivitis during the COVID-19 pandemic 2020 |pdf=|usr=}}
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
{{tp|p=32315229|t=2020. COVID-19 and the CRISPR Community Response |pdf=|usr=}}
 
 
 
 
{{tp|p=32133962|t=2020. Effective Chemicals against Novel Coronavirus (COVID-19) in China |pdf=|usr=}}
 
 
 
{{tp|p=32227357|t=ä. COVID?19 treatment by repurposing drugs until the vaccine is in sight |pdf=|usr=}}
 
{{tp|p=32377559|t=ä. COVID-19: Review of Epidemiology and Potential Treatments Against 2019 Novel Coronavirus |pdf=|usr=}}
 
{{tp|p=32374010|t=2020. Are probiotics effective adjuvant therapeutic choice in patients with COVID-19?|pdf=|usr=}}
 
{{tp|p=32374009|t=2020. Potential mechanisms by which the oxygen-ozone (O2-O3) therapy could contribute to the treatment against the coronavirus COVID-19 |pdf=|usr=}}
 
{{tp|p=32369103|t=ä. Sacubitril/valsartan in COVID-19 patients: the need for trials |pdf=|usr=}}
 
{{tp|p=32373994|t=2020. Could host cell receptor alteration prevent SARS-CoV-2 viral entry? - Hype or hope |pdf=|usr=}}
 
{{tp|p=32373992|t=2020. MSCs transplantation may be a potential therapeutic strategy for COVID-19 treatment |pdf=|usr=}}
 
 
{{tp|p=32362193|t=2020. Quadruple therapy for asymptomatic COVID-19 infection patients |pdf=|usr=}}
 
{{tp|p=32366131|t=2020. Harnessing the potential of CRISPR-based platforms to advance the field of hospital medicine |pdf=|usr=}}
 
{{tp|p=32336007|t=2020. DPP4 inhibition: preventing SARS-CoV-2 infection and/or progression of COVID-19?|pdf=|usr=}}
 
{{tp|p=32224164|t=2020. COVID-19 and diabetes: Can DPP4 inhibition play a role?|pdf=|usr=}}
 
 
 
 
 
{{tp|p=32281695|t=2020. Existing bitter medicines for fighting 2019-nCoV-associated infectious diseases |pdf=|usr=}}
 
{{tp|p=32379896|t=2020. Knowledge-based structural models of SARS-CoV-2 proteins and their complexes with potential drugs |pdf=|usr=}}
 
 
{{tp|p=32157732|t=ä. Harnessing the immune system via Fc?R function in immune therapy: a pathway to next?gen mAbs |pdf=|usr=}}
 
 
{{tp|p=32298218|t=2020. Potential for developing a SARS-CoV receptor-binding domain (RBD) recombinant protein as a heterologous human vaccine against coronavirus infectious disease (COVID)-19 |pdf=|usr=}}
 
{{tp|p=32317431|t=2020. Therapeutic opportunities to manage COVID-19/SARS-CoV-2 infection: Present and future |pdf=|usr=}}
 
{{tp|p=32370727|t=2020. SARS-CoV-2 & Covid-19: Key-Roles of the  Renin-Angiotensin  System / Vitamin D Impacting Drug and Vaccine Developments |pdf=|usr=}}
 
{{ttp|p=32377694|t=2020. Towards effective COVID19 vaccines: Updates, perspectives and challenges (Review) |pdf=|usr=}}
 
{{tp|p=32338559|t=2020. Low dose radiation therapy for COVID-19 pneumonia: is there any supportive evidence?|pdf=|usr=}}
 
 
{{tp|p=32310190|t=2020. Coronavirus drugs: Using plasma from recovered patients as a treatment for COVID-19 |pdf=|usr=}}
 
 
 
 
{{tp|p=32306822|t=2020. Peptide-like and small-molecule inhibitors against Covid-19 |pdf=|usr=}}
 
 
 
 
 
 
{{tp|p=32364041|t=2020. Using integrated computational approaches to identify safe and rapid treatment for SARS-CoV-2 |pdf=|usr=}}
 
 
 
 
 
 
 
 
 
 
 
 
üüp
 
 
{{tp|p=32349031|t=2020. Role of Dipeptidyl Peptidase 4 Inhibitors in Diabetic Patients with Coronavirus-19 Infection |pdf=|usr=}}
 
 
{{tp|p=32379348|t=2020. 3CL hydrolase-based multiepitope peptide vaccine against SARS-CoV-2 using immunoinformatics |pdf=|usr=}}
 
 
 
{{tp|p=32219882|t=ä. Controversial treatments: An updated understanding of the coronavirus disease 2019 |pdf=|usr=}}
 
 
{{tp|p=32108352|t=ä. Clinical trial analysis of 2019?nCoV therapy registered in China |pdf=|usr=}}
 
 
 
 
{{tp|p=32356910|t=2020. Convalescent plasma transfusion for the treatment of COVID-19: Systematic review |pdf=|usr=}}
 
 
 
 
 
 
{{tp|p=32239514|t=ä. Comments on Zhang et al: Clinical trial analysis of 2019?nCoV therapy registered  in China |pdf=|usr=}}
 
 
{{ttp|p=32378064|t=ä. Feasibility of Therapeutic Effects of the Cholinergic Anti-Inflammatory Pathway on COVID-19 Symptoms |pdf=|usr=}}
 
{{tp|p=32320059|t=2020. Potential of live pathogen vaccines for defeating the COVID-19 pandemic: history  and mechanism |pdf=|usr=}}
 
 
{{tp|p=32297985|t=2020. Evaluation of Antiviral Therapies for Coronavirus Disease 2019 (COVID-19) Pneumonia in Shanghai, China |pdf=|usr=}}
 
 
{{tp|p=32293713|t=2020. Treatment with convalescent plasma for COVID-19 patients in Wuhan, China |pdf=|usr=}}
 
{{tp|p=32285942|t=2020. Defining Protective Epitopes for COVID-19 Vaccination Models |pdf=|usr=}}
 
{{tp|p=32281679|t=2020. COVID-19: Herd Immunity and Convalescent Plasma Transfer Therapy |pdf=|usr=}}
 
 
 
 
 
{{tp|p=32380023|t=ä. Immunomodulation in COVID-19 |pdf=|usr=}}
 
{{tp|p=32367857|t=2020. Safety of an immunomodulator Mycobacterium w in COVID-19 |pdf=|usr=}}
 
{{tp|p=32367847|t=2020. Nasopharyngeal wash in preventing and treating upper respiratory tract infections: Could it prevent COVID-19?|pdf=|usr=}}
 
{{tp|p=32371362|t=2020. Mesenchymal stem cell (MSc) secretome: A possible therapeutic strategy for intensive-care COVID-19 patients |pdf=|usr=}}
 
{{tp|p=32366816|t=2020. An Evidence Based Perspective on mRNA-SARS-CoV-2 Vaccine Development |pdf=|usr=}}
 
{{tp|p=32376359|t=ä. Design of a peptide-based subunit vaccine against novel coronavirus SARS-CoV-2 |pdf=|usr=}}
 
{{tp|p=32219429|t=2020. Convalescent Plasma to Treat COVID-19: Possibilities and Challenges |pdf=|usr=}}
 
{{tp|p=32352484|t=2020. Testing an Old Therapy Against a New Disease: Convalescent Plasma for COVID-19 |pdf=|usr=}}
 
{{tp|p=32208486|t=2020. Treating COVID-19-Off-Label Drug Use, Compassionate Use, and Randomized Clinical  Trials During Pandemics |pdf=|usr=}}
 
{{tp|p=32297900|t=2020. Finding Effective Treatments for COVID-19: Scientific Integrity and Public Confidence in a Time of Crisis |pdf=|usr=}}
 
{{tp|p=32282022|t=2020. Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review |pdf=|usr=}}
 
 
{{tp|p=32243778|t=2020. Ensuring global access to COVID-19 vaccines |pdf=|usr=}}
 
{{tp|p=32247324|t=2020. Global coalition to accelerate COVID-19 clinical research in resource-limited settings |pdf=|usr=}}
 
 
{{tp|p=32372435|t=2020. Drug repurposing in the era of COVID-19: a call for leadership and government investment |pdf=|usr=}}
 
 
{{tp|p=32324177|t=2020. Some drugs for COVID-19 |pdf=|usr=}}
 
 
 
{{tp|p=32375002|t=ä. Deconvoluting Lipid Nanoparticle Structure for Messenger RNA Delivery |pdf=|usr=}}
 
{{ttp|p=32378459|t=2020. Application of nanomaterials in treatment, anti-infection and detection of coronaviruses |pdf=|usr=}}
 
{{ttp|p=32363750|t=2020. A Chemographic Audit of anti-Coronavirus Structure-Activity Information from Public Databases (ChEMBL) |pdf=|usr=}}
 
 
{{tp|p=32227757|t=2020. Developing Covid-19 Vaccines at Pandemic Speed |pdf=|usr=}}
 
{{tp|p=32289216|t=2020. Drug Evaluation during the Covid-19 Pandemic |pdf=|usr=}}
 
 
 
{{tp|p=32273591|t=2020. The COVID-19 vaccine development landscape |pdf=|usr=}}
 
{{tp|p=32269311|t=2020. Coordinating the COVID-19 pipeline |pdf=|usr=}}
 
{{tp|p=32127666|t=2020. Therapeutic options for the 2019 novel coronavirus (2019-nCoV) |pdf=|usr=}}
 
 
 
 
{{tp|p=32355243|t=2020. Scores of coronavirus vaccines are in competition - how will scientists choose the best?|pdf=|usr=}}
 
{{tp|p=32353859|t=2020. A SARS-CoV-2 protein interaction map reveals targets for drug repurposing |pdf=|usr=}}
 
{{tp|p=32300225|t=2020. On the front lines of the coronavirus-vaccine battle |pdf=|usr=}}
 
{{tp|p=32346146|t=2020. The race for coronavirus vaccines: a graphical guide |pdf=|usr=}}
 
 
{{tp|p=32377399|t=2020. COVID-19 vaccines: breaking record times to first-in-human trials |pdf=|usr=}}
 
{{tp|p=32297843|t=2020. Oligonucleotides and the COVID-19 Pandemic: A Perspective |pdf=|usr=}}
 
 
{{tp|p=32275178|t=2020. Harnessing innate immunity to eliminate SARS-CoV-2 and ameliorate COVID-19 disease |pdf=|usr=}}
 
{{tp|p=32216577|t=2020. Artificial intelligence and machine learning to fight COVID-19 |pdf=|usr=}}
 
 
{{tp|p=32352615|t=2020. Povidone-iodine gargle as a prophylactic intervention to interrupt the transmission of SARS-CoV-2 |pdf=|usr=}}
 
 
 
 
 
{{tp|p=32259313|t=2020. Review of Emerging Pharmacotherapy for the Treatment of Coronavirus Disease 2019 |pdf=|usr=}}
 
 
 
{{tp|p=32295694|t=2020. COVID-19 vaccination clinical trials should consider multiple doses of BCG |pdf=|usr=}}
 
{{tp|p=32326830|t=2020. Photobiomodulation and Antiviral Photodynamic Therapy as a Possible Novel Approach in COVID-19 Management |pdf=|usr=}}
 
{{tp|p=32330404|t=2020. Can Transdermal Photobiomodulation Help Us at the Time of COVID-19?|pdf=|usr=}}
 
 
 
 
{{tp|p=32374874|t=ä. COVID-19: an unexpected indication for anti-rheumatic therapies?|pdf=|usr=}}
 
{{tp|p=32376603|t=ä. Development of an inactivated vaccine candidate for SARS-CoV-2 |pdf=|usr=}}
 
 
 
{{tp|p=32301312|t=2020. Vaccins anti-covid-19 : les recherches de johnson & johnson, sanofi et pasteur |pdf=|usr=}}
 
{{tp|p=32355008|t=2020. COVID-19 shot protects monkeys |pdf=|usr=}}
 
{{tp|p=32292113|t=2020. Stem Cell?Based Therapy for Coronavirus Disease 2019 |pdf=|usr=}}
 
{{tp|p=32272857|t=2020. Role of Tissue Engineering in COVID-19 and Future Viral Outbreaks |pdf=|usr=}}
 
 
{{tp|p=32302280|t=2020. Brief Summary of Potential SARS-CoV-2 Prophylactic and Treatment Drugs in the Emergency Department |pdf=|usr=}}
 
{{tp|p=32220178|t=2020.  Biological Product Development Strategies for Prevention and Treatment of Coronavirus Disease 2019  |pdf=|usr=}}
 
{{tp|p=32374891|t=2020. Convalescent plasma to treat coronavirus disease 2019 (COVID-19): considerations  for clinical trial design |pdf=|usr=}}
 
{{tp|p=32374890|t=2020. COVID-19 convalescent plasma: phase 2 |pdf=|usr=}}
 
{{tp|p=32245869|t=2020. Possible treatment of Covid-19 with a therapeutic vaccine |pdf=|usr=}}
 
{{tp|p=32221001|t=2020. Possible method for the production of a Covid-19 vaccine |pdf=|usr=}}
 
{{tp|p=32324899|t=2020. Operational protocol for donation of anti-COVID-19 convalescent plasma in Italy |pdf=|usr=}}
 
{{tp|p=32319102|t=2020. Points to consider in the preparation and transfusion of COVID-19 convalescent plasma |pdf=|usr=}}
 
{{tp|p=32240545|t=2020. Collecting and evaluating convalescent plasma for COVID-19 treatment: why and how?|pdf=|usr=}}
 
{{ttp|p=32281329|t=2020.  Study on treatment of "cytokine storm" by anti-2019-nCoV prescriptions based on  arachidonic acid metabolic pathway  |pdf=|usr=}}
 
 
{{tp|p=32164080|t=2020.  Potential antiviral therapeutics for 2019 Novel Coronavirus  |pdf=|usr=}}
 
{{tp|p=32164081|t=2020.  Pharmacotherapeutics for the new coronavirus pneumonia  |pdf=|usr=}}
 
{{tp|p=32164077|t=2020.  Pharmacotherapeutic about the new coronavirus pneumonia  |pdf=|usr=}}
 
 
{{tp|p=32234130|t=2020.  Progress and challenge of vaccine development against 2019 novel coronavirus (2019-nCoV)  |pdf=|usr=}}
 
 
{{tp|p=C7180667|t=ä. Achilles  heel of the killer virus: the highly important molecular targets for hitting SARS-CoV-2 that causes COVID-19 |pdf=|usr=}}
 
{{tp|p=C7190525|t=2020. Adjunct Immunotherapies for the Management of Severely Ill COVID-19 Patients |pdf=|usr=}}
 
{{tp|p=C7152890|t=2020. Biomimetic nanoparticles as universal influenza vaccine |pdf=|usr=}}
 
 
{{tp|p=C7187737|t=ä. COVID-19 and the Rationale for Pharmacotherapy: A South African Perspective |pdf=|usr=}}
 
{{tp|p=C7167691|t=2020. (Deutsche Szene) Schutz vor und Hilfe bei Covid19 Infektionen |pdf=|usr=}}
 
 
 
 
 
{{tp|p=C7189010|t=2020. Biologika und Covid-19 |pdf=|usr=}}
 
 
 
 
{{tp|p=32387535|t=ä. Asthma, biologics, corticosteroids, and coronavirus disease 2019 |pdf=|usr=}}
 
 
{{tp|p=C7197606|t=ä. Antibody therapies for the treatment of COVID-19 |pdf=|usr=}}
 
 
{{tp|p=32380316|t=2020. Convalescent plasma in Covid-19: Possible mechanisms of action |pdf=|usr=}}
 
 
 
{{tp|p=32376392|t=2020. Should we stimulate or suppress immune responses in COVID-19? Cytokine and anti-cytokine interventions |pdf=|usr=}}
 
 
{{tp|p=32389697|t=ä. Plasmapheresis treatment in COVID-19?related autoimmune meningoencephalitis: Case series |pdf=|usr=}}
 
 
{{tp|p=32437659|t=2020. Trained Immunity: a Tool for Reducing Susceptibility to and the Severity of SARS-CoV-2 Infection |pdf=|usr=}}
 
{{ttp|p=32402856|t=2020. Could an endo-lysosomal ion channel be the Achilles heel of SARS-CoV2?|pdf=|usr=}}
 
 
{{tp|p=C7151553|t=2020. COVID-19 Coronavirus spike protein analysis for synthetic vaccines, a peptidomimetic antagonist, and therapeutic drugs, and analysis of a proposed achilles? heel conserved region to minimize probability of escape mutations and drug resistance |pdf=|usr=}}
 
 
{{tp|p=32129977|t=2020. Cell-Membrane-Mimicking Nanodecoys against Infectious Diseases |pdf=|usr=}}
 
{{tp|p=29115746|t=2018. Progress Toward the Clinical Translation of Bioinspired Peptide and Protein Assemblies |pdf=|usr=}}
 
{{tp|p=29717819|t=2018. Recent Advances in the Development of Antimicrobial Nanoparticles for Combating Resistant Pathogens |pdf=|usr=}}
 
{{tp|p=28945945|t=2017. Macromolecular Antiviral Agents against Zika, Ebola, SARS, and Other Pathogenic Viruses |pdf=|usr=}}
 
 
{{tp|p=21093489|t=2011. (x)Single-dose intranasal administration with mDEF201 (adenovirus vectored mouse interferon-alpha) confers protection from mortality in a lethal SARS-CoV BALB/c mouse model |pdf=|usr=}}
 
{{tp|p=20727913|t=2010. (x)Identification of phenanthroindolizines and phenanthroquinolizidines as novel potent anti-coronaviral agents for porcine enteropathogenic coronavirus transmissible gastroenteritis virus and human severe acute respiratory syndrome coronavirus |pdf=|usr=}}
 
 
{{tp|p=31073993|t=2019. (x)Synthesis and anti?coronavirus activity of a series of 1?thia?4?azaspiro 4 5 decan?3?one derivatives |pdf=|usr=}}
 
 
*[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3335060/ Immunization with SARS Coronavirus Vaccines Leads to Pulmonary Immunopathology on Challenge with the SARS Virus btu @OnlyTheGhosts]
 
{{tp|p=32285908|t=2020. Chloroquine and bafilomycin A mimic lysosomal storage disorders and impair mTORC1 signalling |pdf=|usr=}}
 
 
{{tp|p=32243785|t=2020. Embracing the Landscape of Therapeutics |pdf=|usr=}}
 
 
 
{{tp|p=30993690|t=2019. Emerging viruses and current strategies for vaccine intervention |pdf=|usr=}}
 
 
{{tp|p=32099652|t=2020. Frontiers in antiviral therapy and immunotherapy |pdf=|usr=}}
 
 
{{tp|p=32259744|t=2020. DNA vaccines: prime time is now |pdf=|usr=}}
 
{{tp|p=32387642|t=2020. Innovations in structure-based antigen design and immune monitoring for next generation vaccines |pdf=|usr=}}
 
{{tp|p=C7163352|t=ä. Cell-Based Therapies for COVID-19: Proper Clinical Investigations are Essential |pdf=|usr=}}
 
 
{{tp|p=32382358|t=ä. COVID-19 and Diabetes Mellitus: May Old Anti-diabetic Agents Become the New Philosopher?s Stone?|pdf=|usr=}}
 
{{tp|p=32377559|t=ä. COVID-19: Review of Epidemiology and Potential Treatments Against 2019 Novel Coronavirus |pdf=|usr=}}
 
{{tp|p=32387262|t=ä. Extracellular vesicles from mesenchymal stem cells as a Covid-19 treatment |pdf=|usr=}}
 
{{tp|p=C7194243|t=ä. Coronavirus Disease 2019 (COVID-19) Spread and Pharmacovigilance Implications: Expert Opinion |pdf=|usr=}}
 
{{tp|p=32383008|t=ä. The Role of Pharmacovigilance and ISoP During the Global COVID-19 Pandemic |pdf=|usr=}}
 
{{tp|p=32344202|t=2020. Impact of immune enhancement on Covid-19 polyclonal hyperimmune globulin therapy  and vaccine development |pdf=|usr=}}
 
 
{{tp|p=C7118608|t=ä. A Promising Anti-Cytokine-Storm Targeted Therapy for COVID-19: The Artificial-Liver Blood-Purification System |pdf=|usr=}}
 
 
 
{{tp|p=C7117595|t=ä. Drug repurposing strategies for COVID-19 |pdf=|usr=}}
 
 
{{tp|p=16022774|t=2005. (+)SARS Vaccine Development |pdf=|usr=}}
 
{{tp|p=28861908|t=2017. (+)Issues in vaccinology: Present challenges and future directions |pdf=|usr=}}
 
 
{{tp|p=16433589|t=2006. (+)Antiviral applications of RNAi for coronavirus |pdf=|usr=}}
 
{{tp|p=32318055|t=2020. Better Epitope Discovery, Precision Immune Engineering, and Accelerated Vaccine Design Using Immunoinformatics Tools |pdf=|usr=}}
 
 
{{tp|p=32362826|t=2020. Editorial: New Advances in RNA Targeting |pdf=|usr=}}
 
{{tp|p=32201439|t=2020. Therapeutic options for the treatment of 2019-novel coronavirus: An evidence-based approach |pdf=|usr=}}
 
 
{{tp|p=32081774|t=2020. Discovery and development of safe-in-man broad-spectrum antiviral agents |pdf=|usr=}}
 
 
 
 
 
{{tp|p=32386655|t=2020. Influence of immune aging on vaccine responses |pdf=|usr=}}
 
 
 
 
 
 
 
{{tp|p=32281318|t=2020. Convalescent Plasma Therapy for Corona Virus Disease 2019: a Long Way to Go but Worth Trying |pdf=|usr=}}
 
 
{{tp|p=32105468|t=2020. Structure-Based Stabilization of Non-native Protein?Protein Interactions of Coronavirus Nucleocapsid Proteins in Antiviral Drug Design |pdf=|usr=}}
 
 
{{tp|p=16697221|t=2006. (+)Template-based coiled-coil antigens elicit neutralizing antibodies to the SARS-coronavirus |pdf=|usr=}}
 
 
{{tp|p=32388486|t=2020. Light as a potential treatment for pandemic coronavirus infections: A perspective |pdf=|usr=}}
 
{{tp|p=C7202831|t=ä. Testing COVID-19 therapies to prevent progression of mild disease |pdf=|usr=}}
 
{{tp|p=C7202844|t=ä. Vaccine development during global epidemics: the Zika experience |pdf=|usr=}}
 
{{tp|p=32380023|t=ä. Immunomodulation in COVID-19 |pdf=|usr=}}
 
{{tp|p=32444269|t=ä. Immunotherapies for COVID-19: lessons learned from sepsis |pdf=|usr=}}
 
{{tp|p=32409074|t=2020. An overview of functional nanoparticles as novel emerging antiviral therapeutic agents |pdf=|usr=}}
 
{{tp|p=C7190528|t=ä. Treatment Considerations for COVID-19: A Critical Review of the Evidence (or Lack Thereof) |pdf=|usr=}}
 
 
 
 
 
{{tp|p=32373787|t=2020. A new paradigm for drug development |pdf=|usr=}}
 
{{tp|p=32359447|t=2020. The resurgence of convalescent plasma therapy |pdf=|usr=}}
 
{{tp|p=32325038|t=ä. (+)Safety and immunogenicity of a candidate Middle East respiratory syndrome coronavirus viral-vectored vaccine: a dose-escalation, open-label, non-randomised, uncontrolled, phase 1 trial |pdf=|usr=}}
 
{{tp|p=32325036|t=ä. Two Middle East respiratory syndrome vaccines: first step for other coronavirus vaccines?|pdf=|usr=}}
 
{{ttp|p=29329956|t=2018. Herd immunity: hyperimmune globulins for the 21st century |pdf=|usr=}}''megapool for the top useful human mab''
 
{{tp|p=31351923|t=2019. (+)First clinical trial of a MERS coronavirus DNA vaccine |pdf=|usr=}}
 
{{tp|p=28664850|t=2017. (+)Novel translational approaches to the search for precision therapies for acute respiratory distress syndrome |pdf=|usr=}}
 
 
{{tp|p=29852530|t=2020. The expanding role of mass spectrometry in the field of vaccine development |pdf=|usr=}}
 
{{tp|p=31432544|t=2020. Repurposing approved drugs on the pathway to novel therapies |pdf=|usr=}}
 
{{tp|p=31692019|t=2020. (+)Gold nanoparticle?adjuvanted S protein induces a strong antigen?specific IgG response against severe acute respiratory syndrome?related coronavirus infection, but fails to induce protective antibodies and limit eosinophilic infiltration in  lungs |pdf=|usr=}}
 
 
{{tp|p=32197324|t=2020. A Review on Applications of Computational Methods in Drug Screening and Design |pdf=|usr=}}
 
{{tp|p=20956884|t=2010. (+)Small Interfering RNA Effectively Inhibits the Expression of SARS Coronavirus Membrane Gene at Two Novel Targeting Sites |pdf=|usr=}}
 
{{tp|p=32317764|t=ä. Developing therapeutic monoclonal antibodies at pandemic pace |pdf=|usr=}}
 
 
 
 
 
 
 
 
 
{{tp|p=32387334|t=ä. The Forrest Gump approach to preventing severe COVID-19 ? reverse the predisposing pro-inflammatory state with exercise |pdf=|usr=}}
 
{{tp|p=32376359|t=2020. Design of a peptide-based subunit vaccine against novel coronavirus SARS-CoV-2 |pdf=|usr=}}
 
 
{{tp|p=32382315|t=2020. Can graphene take part in the fight against COVID-19?|pdf=|usr=}}
 
{{tp|p=32313660|t=2020. A short review on antibody therapy for COVID-19 |pdf=|usr=}}
 
{{tp|p=32377399|t=2020. COVID-19 vaccines: breaking record times to first-in-human trials |pdf=|usr=}}
 
 
 
{{tp|p=32380052|t=2020. Granulocyte-targeted therapies for airway diseases |pdf=|usr=}}
 
{{tp|p=32389754|t=ä. (low dose radiat)RILI model and the Covid-19 pneumonia: The radiation oncologist point of view? |pdf=|usr=}}
 
{{tp|p=32387544|t=ä. Response to: Low dose radiation therapy for COVID-19 pneumonia a double-edged sword? |pdf=|usr=}}
 
 
 
 
 
 
{{tp|p=32448638|t=2020. Convalescent plasma, an apheresis research project targeting and motivating the fully recovered COVID 19 patients: A rousing message of clinical benefit to both  donors and recipients alike |pdf=|usr=}}
 
{{tp|p=32417123|t=ä. Convalescent plasma, an apheresis research project targeting and motivating the fully recovered COVID 19 patients: A rousing message of clinical benefit to both  donors and recipients alike |pdf=|usr=}}
 
{{tp|p=32418793|t=2020. An effective CTL peptide vaccine for Ebola Zaire Based on Survivors? CD8+ targeting of a particular nucleocapsid protein epitope with potential implications for COVID-19 vaccine design |pdf=|usr=}}
 
{{tp|p=32381478|t=2020. Enabling emergency mass vaccination: Innovations in manufacturing and administration during a pandemic |pdf=|usr=}}
 
{{tp|p=32452420|t=2020. Antiviral activity of lycorine against Zika virus in vivo and in vitro |pdf=|usr=}}
 
 
 
{{tp|p=32061923|t=2020. Dipeptidyl peptidase 4 inhibitors and their potential immune modulatory functions |pdf=|usr=}}
 
 
 
{{tp|p=32208449|t=2020. BRD4 inhibition exerts anti-viral activity through DNA damage-dependent innate immune responses |pdf=|usr=}}
 
{{tp|p=32355446|t=2020. Medicaments rhumatologiques pour le traitement de l?infection par le COVID-19? |pdf=|usr=}}
 
 
{{tp|p=16043204|t=2005. (+)Long-term protection from SARS coronavirus infection conferred by a single immunization with an attenuated VSV-based vaccine |pdf=|usr=}}
 
{{tp|p=31930543|t=2020. Inactivation of three emerging viruses ? severe acute respiratory syndrome coronavirus, Crimean?Congo haemorrhagic fever virus and Nipah virus ? in platelet concentrates by ultraviolet C light and in plasma by methylene blue plus visible  light |pdf=|usr=}}
 

Version vom 3. Oktober 2020, 20:18 Uhr

coviki.org collects the really good Ideas and the scientific Record on Covid-19 Virus.

 P further streaming-in related content is here

...so calm down and enjoy the progress of immediate translational medicine:

A concept of curative retargeting has been found by cellular lockdown with kinase inhibitors from the oncologic pharmacopoiea.
This means, virus replication can be stalled to zero w/o need of develpoment of new substances. There is no need for world
vaccination anymore. The virus needs permissible cells, and most perimissible is phosphotyrosine on its own compnents.
Paper is (not yet in PubMed) :

credentials to Marinus Brandl who told us about it today. based on e.g.

32408336 2020. Proteomics of SARS-CoV-2-infected host cells reveals therapy targets
=======================================================================================
COVID19 is now a CURABLE disease !!!
=======================================================================================





Meine Werkzeuge
Namensräume
Varianten
Aktionen
Navigation
Werkzeuge
Blogverzeichnis - Blog Verzeichnis bloggerei.deBlogverzeichnis